Nebivololo Tecnigen (Nebivolol Hydrochloride)

Nebivolol is indicated for conditions related to the cardiovascular system, primarily hypertension.

• Hypertension: reduces systolic and diastolic blood pressure, helping achieve target levels.
• Essential hypertension: provides consistent blood pressure control in patients with primary hypertension.
• Isolated systolic hypertension: lowers elevated systolic pressure, particularly in older adults.

• Nebivolol acts as a selective β1‑adrenergic receptor antagonist, decreasing heart rate and myocardial contractility, which reduces cardiac output. In addition, it stimulates endothelial nitric oxide synthase, leading to nitric‑oxide‑mediated vasodilation. The combined β‑blockade and vasodilatory effect lowers peripheral vascular resistance and systemic blood pressure, providing antihypertensive activity without significant β2‑related bronchoconstriction. The drug’s high β1 selectivity minimizes impact on β2 receptors in the lungs, and the nitric‑oxide pathway contributes to improved endothelial function.

Nebivolol may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate pain in the head.
• Dizziness: sensation of light‑headedness or imbalance.
• Fatigue: feeling of tiredness or reduced energy.
• Nasal congestion: blockage or runny nose.
• Bradycardia: slower than normal heart rate.
• Nausea: upset stomach with urge to vomit.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Symptomatic hypotension: significant drop in blood pressure causing faintness.
• Heart block: impairment of electrical conduction in the heart.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Liver injury: elevated enzymes or hepatitis.
• Cardiogenic shock: rare but life‑threatening circulatory failure.

When prescribing Nebivololo Tecnigen, clinicians should consider several precautionary measures to ensure patient safety.

• Blood pressure monitoring: check baseline and periodic readings to assess response.
• Cardiac function assessment: evaluate for existing bradycardia or heart block before initiation.
• Asthma or chronic obstructive pulmonary disease: use with caution due to potential β‑blockade effects on airways.
• Abrupt discontinuation: avoid sudden stop to prevent rebound hypertension.
• Renal or hepatic impairment: dose adjustment may be required based on organ function.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Other β‑blockers: additive bradycardia and hypotension.
• Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV‑block and severe bradycardia.
• Clonidine withdrawal: may cause rebound hypertension if stopped abruptly while on nebivolol.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: additive blood‑pressure lowering effect.
• Diuretics: may enhance hypotensive response and electrolyte disturbances.
• NSAIDs: can attenuate antihypertensive effect of nebivolol.
• Antidiabetic agents: may mask hypoglycemia symptoms.